Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Public ClinicalTrials.gov record NCT06712407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done
Study identification
- NCT ID
- NCT06712407
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2024 (Actual)
- Primary completion
- Mar 2027 (Estimated)
- Completion
- Feb 2028 (Estimated)
- Last update posted
- Sep 24, 2026
2024 – 2028
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ of Alabama/Birmingham | Birmingham | Alabama | 35297 | — |
| Arizona Kidney Disease & Hypertension Centers (AKDHC) | Glendale | Arizona | 85306 | — |
| The Medical Research Group, Inc. | Fresno | California | 93720 | — |
| UCI Health-UCI Medical Center | Orange | California | 92868 | — |
| Loma Linda University | San Bernardino | California | 92408 | — |
| UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice | San Francisco | California | 94143 | — |
| Stanford University | Stanford | California | 94305 | — |
| University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location | Aurora | Colorado | 80045 | — |
| Yale University Nephrology Clinical Trials Program | New Haven | Connecticut | 06510 | — |
| Florida Kidney Physicians | Boca Raton | Florida | 33431 | — |
| Central Florida Kidney Specialists | Orlando | Florida | 32819 | — |
| Southeastern Clinical Research Institute, LLC | Augusta | Georgia | 30904 | — |
| Cobb Nephrology Hypertension Associates, PC | Austell | Georgia | 30106 | — |
| Georgia Nephrology | Lawrenceville | Georgia | 30046 | — |
| University of Louisville | Louisville | Kentucky | 40208 | — |
| Ochsner Health, New Orleans | New Orleans | Louisiana | 70121 | — |
| University of Maryland Division of Nephrology | Baltimore | Maryland | 21201 | — |
| Boston Medical Center; Boston University Chobanian & Avedisian School of Medicine | Boston | Massachusetts | 02118 | — |
| University of Minnesota Health Fairview | Minneapolis | Minnesota | 55455 | — |
| Washington University in St. Louis | St Louis | Missouri | 63130 | — |
| University of New Mexico | Albuquerque | New Mexico | 87106 | — |
| Renal Medical Associates | Albuquerque | New Mexico | 87109 | — |
| New York Nephrology Vasculitis and Glomerular Center | Clifton Park | New York | 12065 | — |
| Chinatown Kidney Care, PLLC | New York | New York | 10013 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| North Carolina Nephrology, P.A | Raleigh | North Carolina | 27609 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic | Portland | Oregon | 97239 | — |
| University of Pennsylvania Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Dallas Renal Group | Dallas | Texas | 75230 | — |
| MedResearch Inc | El Paso | Texas | 79902 | — |
| The University of Texas Medical Branch UTMB | Galveston | Texas | 77555 | — |
| Memorial Hermann Houston | Houston | Texas | 77054 | — |
| Prolato Clinical Research Center | Houston | Texas | 77054 | — |
| The Kidney Institute/Houston | Houston | Texas | 77090 | — |
| Dallas Nephrology Associates McKinney | McKinney | Texas | 75069 | — |
| Permian Basin Kidney Center | Odessa | Texas | 79761 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06712407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06712407 live on ClinicalTrials.gov.